Furosemide oral tablet [Regulatives / Guidelines]

posted by Ibrahim Komeil – Egypt, 2019-11-18 10:03 (1846 d 03:08 ago) – Posting: # 20818
Views: 1,675

Dear all

I would like to ask about bioequivalence study for Furosemide oral tablet. It is listed in FDA draft guidance that it is not high variable drug and i can use 2 way crossover design. However, i read EMA guidelines and MHRA guidelines assure its high interasubject variability so they recommend to have partial replicated design applying normal acceptance range (80%-125%), so what do you think about these data upon on your experience ?

Complete thread:

UA Flag
Activity
 Admin contact
23,335 posts in 4,901 threads, 1,670 registered users;
27 visitors (0 registered, 27 guests [including 9 identified bots]).
Forum time: 13:12 CET (Europe/Vienna)

There are many questions which fools can ask
that wise men cannot answer.    George Pólya

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5